微芯生物(688321.SH)：西奥罗尼胶囊治疗转移性胰腺导管腺癌临床试验申请获受理

Core Viewpoint - Microchip Biotech (688321.SH) has received the acceptance notice for the clinical trial application of its self-developed Xioroni capsules for the treatment of metastatic pancreatic ductal adenocarcinoma from the National Medical Products Administration's Drug Evaluation Center [1] Group 1 - The company has recently announced the acceptance of its clinical trial application [1] - The clinical trial is focused on a new drug aimed at treating a specific type of cancer, namely metastatic pancreatic ductal adenocarcinoma [1]